1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,830 | 0,845 | 09.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | LAEKNA-B (02105): INTERIM REPORT 2026 | 2 | HKEx | ||
| 08.09. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 01.09. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE I CLINICAL STUDY OF LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR) | 3 | HKEx | ||
| 25.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 17.08. | LAEKNA-B (02105): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 12.08. | Laekna's breast cancer drug application accepted in China | 1 | Investing.com | ||
| 12.08. | Laekna: New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration | 234 | PR Newswire | SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center... ► Artikel lesen | |
| LAEKNA Aktie jetzt für 0€ handeln | |||||
| 12.08. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR LAE002 (AFURESERTIB) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| 07.08. | LAEKNA-B (02105): DATE OF BOARD MEETING | 3 | HKEx | ||
| 09.07. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.07. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASES UNDER THE REPURCHASE MANDATE AND PROPOSED SHARE PURCHASE BY SENIOR MANAGEMENT | 3 | HKEx | ||
| 29.06. | LAEKNA-B (02105): UPDATE ON QUALIFICATION OF COMPANY SECRETARY; RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE | - | HKEx | ||
| 10.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH VASQUE BIO FOR LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR) IN ... | 2 | HKEx | ||
| 05.06. | LAEKNA-B (02105): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026 | 1 | HKEx | ||
| 14.05. | LAEKNA-B (02105): PROXY FORM FOR THE ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 14.05. | LAEKNA-B (02105): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 14.05. | LAEKNA-B (02105): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF DIRECTORS; ... | - | HKEx | ||
| 11.05. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.05. | LAEKNA-B (02105): GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 15.04. | LAEKNA-B (02105): INSIDE INFORMATION POSITIVE TOPLINE RESULTS PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) MET PRIMARY ENDPOINT OF PFS ... | 1 | HKEx |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | +2,45 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | +14,12 % | Moderna zeigt, wie schwierig der Sprung von der Studie zum Geschäftsmodell ist - ein Biotech aus Australien macht es vor | ||
| NURIX THERAPEUTICS | 22,350 | +0,63 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | +0,29 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | +2,88 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | +5,59 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,645 | +1,68 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | +3,12 % | $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| ABSCI | 10,165 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
LAEKNA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-2,35 %) liegt der Kurs bei 0,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAEKNA INC finden Sie auf Wallstreet Online.